Skip to main content
. 2021 Oct 1;11(10):163. doi: 10.1038/s41408-021-00555-8

Table 1.

Summary of AEs by MedDRA SOC.

AE, n (%) All-grade AEs, ≥ 20% of total patients Grade ≥ 3 AEs, ≥ 20% of total patients SAEs, ≥ 10% of total patients
VEN + LDAC (n = 142) PBO + LDAC (n = 68) VEN + LDAC (n = 142) PBO + LDAC (n = 68) VEN + LDAC (n = 142) PBO + LDAC (n = 68)
Any 141 (99) 67 (99) 138 (97) 65 (96) 95 (67) 42 (62)
Hematologic 115 (81) 51 (75) 111 (78) 50 (74) 33 (23) 16 (24)
Neutropenia 69 (49) 12 (18) 69 (49) 12 (18) 4 (3) 0
Thrombocytopenia 65 (46) 27 (40) 65 (46) 26 (38) 7 (5) 2 (3)
Febrile neutropenia 46 (32) 20 (29) 46 (32) 20 (29) 24 (17) 12 (18)
Anemia 41 (29) 15 (22) 38 (27) 15 (22) 4 (3) 0
Gastrointestinal disorders 106 (75) 47 (69) 19 (13) 6 (9) 10 (7) 1 (1)
Nausea 61 (43) 21 (31) 2 (1) 0 0 0
Diarrhea 47 (33) 12 (18) 4 (3) 0 1 (1) 0
Vomiting 41 (29) 10 (15) 1 (1) 0 0 0
Constipation 29 (20) 22 (32) 1 (1) 0 0 0
Metabolism and nutrition disorders 87 (61) 40 (59) 40 (28) 22 (32) 5 (4) 0
Hypokalemia 44 (31) 17 (25) 17 (12) 11 (16) 0 0
Decreased appetite 31 (22) 13 (19) 2 (1) 0 1 (1) 0
Infections 92 (65) 41 (60) 61 (43) 34 (50) 53 (37) 25 (37)
Pneumonia 31 (22) 11 (16) 25 (18) 11 (16) 20 (14) 7 (10)

AE adverse event, LDAC low-dose cytarabine, MedDRA SOC medical dictionary for regulatory activities system organ class, PBO placebo, SAE, serious AE, VEN venetoclax.